Screener
BridgeBio Pharma BBIO Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Operating lease liabilities, net of current portion | 14,216 | 3,811 |
| Deferred revenue, net of current portion | 11,776 | 13,080 |
| Other long-term liabilities | 229 | 244 |
| Total liabilities | 3,639,856 | 3,012,606 |
| Commitments and contingencies (Note 7) | ||
| Redeemable convertible noncontrolling interests | (951) | (570) |
| Stockholders’ deficit: | ||
| Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | — | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's total liabilities?
- BridgeBio Pharma (BBIO) reported total liabilities of $3.64B in Q1 2026.
- How has BridgeBio Pharma's total liabilities changed year-over-year?
- BridgeBio Pharma's total liabilities increased by 44.4% year-over-year, from $2.52B to $3.64B.
- What is the long-term trend for BridgeBio Pharma's total liabilities?
- Over 5 years (2020 to 2025), BridgeBio Pharma's total liabilities has grown at a 38.3% compound annual growth rate (CAGR), from $595.7M to $3.01B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about BridgeBio Pharma's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude